



**mec**

WOMEN IN DATA

28 03 2024 – Antwerp



# First something about me...



- 2010 Start studying **Bioscience Engineering**
- 2014 Switched to Civil Engineering - Master in **Biomedical Engineering**
- 2016 Master in **AI**
- 2017 Researcher at **VITO** for 5 years  
Focusing on deep learning applied on medical images  
Involved in setting up spinoff company Mona.Health
- 2022 'Shaper' at **imec**  
Setting up collaborations & writing project proposals on the health x AI intersection



Also happy wife of Jonas, loving mother of Flo and side hussling in De goei plek.

# Deep learning for diabetic retinopathy detection

# Diabetic retinopathy




Effects of DR are noticed in a late stage.

An eye scan in combination with image analysis can make an early diagnosis.

The number of people with vision impairment due to DR is growing.

**How do we identify individuals with DR from those without DR?**

# DR detection using deep learning



Diabetic retinopathy	
None (0)	Green
Mild (1)	Light Green
Moderate (2)	Yellow
Severe (3)	Orange
Proliferative (4)	Red
<b>Referral</b>	White

97% AUC, 94% sensitivity, 90% specificity




Peeters et al. (2023). Artificial Intelligence Software for Diabetic Eye Screening: Diagnostic Performance and Impact of Stratification. Journal of Clinical Medicine.

# Possible thanks to large-scale databases




Large US screening program for DR



+80k fundus images graded for DR according to the International Clinical Diabetic Retinopathy Disease Severity Scale

# Even when groundtruth is available, ophthalmologists are inconsistent



Peng, Lily. (2017). Case study: TensorFlow in medicine. Work presented at the Dev Summit Meeting, Mountain View, CA.



# But what to do next?

MIT Technology Review



ARTIFICIAL INTELLIGENCE

**Google's medical AI was super accurate in a lab. Real life was a different story.**

If AI is really going to make a difference to patients we need to know how it works when real humans get their hands on it, in real situations.

By [Will Douglas Heaven](#) April 27, 2020




**Establishing accuracy in a lab is just a first step.**

Beede et al. (2020). A human-centered evaluation of a deep learning system deployed in clinics for the detection of diabetic retinopathy. Conference on Human Factors in Computing Systems.

# AI/ML for drug design and discovery

# NAVIGATING THE CHALLENGE OF DRUG DESIGN & DISCOVERY



## CHALLENGES


Going from hit generation to market approval takes approx. 10-15 years

Going from hit generation to market approval costs 1.3 billion USD on average

Only 7.9% of initial drug candidates are approved for use in humans

# NAVIGATING THE CHALLENGE OF DRUG DESIGN & DISCOVERY

Optimized drug discovery and development funnel



Traditional drug discovery and development funnel

## MISSION DRIVEN INNOVATION

Expand initial pool of drug candidates

Faster selection of high potential candidates

Accelerate design and discovery cycle at reduced total cost

\*Figure adapted from Recursion Pharmaceuticals.

# AI in Drug Discovery in the news


## AI Takes On Drug Discovery

June 9, 2023

### Race for First Drug Discovered Nears Key Milestone

- AI helped Insilico speed up discovery, cut costs for lun
- Insilico straddles geopolitical faultlines across borders

### From Start to Phase 1 in 30 Months: AI-discovered and AI-designed Anti-fibrotic Drug Enters Phase I Clinical Trial




Alex Zhavoronkov, founder and CEO of Insilico Medicine, at the company's AI-run robotic laboratory in Suzhou, China. Photographer: Qilai Shen/Bloomberg



# Drug design and discovery

Based on activity screening



Target protein involved in disease pathway


WET LAB



PHYSICS-BASED SIMULATIONS



PROPERTY PREDICTION



DRUG CANDIDATE

# So we solve it with AI

... But do we really?

## AI-created drugs fall off hype cycle

Paige Twenter - Friday, October 20th, 2023

[AI-created drugs fall off hype cycle \(beckershospitalreview.com\)](https://www.beckershospitalreview.com)

**ENDPOINTS in FOCUS**

### After years of hype, the first AI-designed drugs fall short in the clinic

Andrew Dunn  
Biopharma Correspondent

The first AI-designed drugs have ended with disappointment.

**AI's potential to accelerate drug discovery needs a reality check**

Companies say the technology will contribute to faster drug development. Independent verification and clinical trials will determine whether this claim holds up.

**Have AI drug discovery startups delivered on their promise 10 years on?**


Artificial intelligence promises to make drug discovery much faster and more efficient, but the pharma industry is still waiting for proof.

### AI in DD — where are the success stories?

Leo Wossnig · Follow  
8 min read · 2 days ago

[AI in DD — where are the success stories? | by Leo Wossnig | Oct, 2023 | Medium](#)

**ENDPOINTS NEWS** CHANNELS WEBINARS BIOPHARMA JOBS MORE



A scientist designing a new protein using computer software

October 19, 2023 09:37 AM EDT Updated 11:05 AM | AI, In Focus

**ENDPOINTS in FOCUS**

### After years of hype, the first AI-designed drugs fall short in the clinic

Andrew Dunn  
Biopharma Correspondent

The first AI-designed drugs have ended with disappointment.

[First AI-designed drugs fall short in the clinic, following years of hype – Endpoints News \(endpts.com\)](https://endpts.com)





Personal advice



Don't be afraid to ask advice



Follow your gut  
& be kind to yourself



mtec

embracing a better life